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Abstract 
 
This work demonstrates for the first time that binding of various compounds within 
subdomain IB of human serum albumin (HSA) provokes characteristic changes in the near-
UV circular dichroism (CD) spectrum of the protein. It can be inferred from the spectroscopic 
features of difference ellipticity signals and from CD displacement experiments that tyrosine 
residues located in subdomain IB are the source of the observed CD spectral alterations. It is 
proposed that inclusion of some ligand molecules (bile acids, dehydroepiandrosterone sulfate, 
steroidal terpenes, fatty acids, ibuprofen, and gemfibrozil) into the pocket of subdomain IB 
disrupts the Tyr138-Tyr161 interhelical π-π stacking interaction which is reflected in the CD 
spectrum. This phenomenon can be utilized for the CD detection of subdomain IB specific 
binding of endo- as well as exogenous agents and to study the drug binding associated local 
conformational adaptation of the HSA molecule. 
 
 
 
Keywords: human serum albumin; bile acid; carbenoxolone; circular dichroism; 
dehydroepiandrosterone sulfate; fatty acid; gemfibrozil; glycyrrhetinic acid; 
ibuprofen; subdomain IB; tyrosine side chain 
 
Abbreviations: CD, circular dichroism; CHN, chenodeoxycholic acid; CRB, carbenoxolone; 
dehydroepiandrosterone sulfate, (DHEAS); FA, fatty acid; GCHN, 
glycochenodeoxycholic acid; GLC, 18β-glycyrrhetinic acid; HSA, human 
serum albumin; ICD, induced circular dichroism; URS, ursodeoxycholic acid 
 
Page 2 of 33
ACS Paragon Plus Environment
The Journal of Physical Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
1 
Introduction 
 
Human serum albumin (HSA) is a ubiquitous constituent of blood serum where it is present in 
millimolar concentration (~0.6 mM). The single polypeptide chain of HSA is folded into a 
multidomain structure composed from three homologous domains (I-III), each of which is 
divided into two subdomains, termed A and B, having six and four α-helices, respectively. 
HSA accounts for the binding and transportation of a large number of chemical entities 
including pharmaceutical substances as well as endogenous compounds. Two principal drug 
binding regions of HSA called as Sudlow’s sites were described several decades ago and  
characterized extensively by huge number of solution binding studies.
1-4
 Subsequently, X-ray 
crystallographic investigations provided high-resolution insight into the architecture and 
ligand binding properties of these pockets situated in subdomain IIA (site IIA) and IIIA (site 
IIIA), respectively.
5-11
 In addition, the existence of a third, separate ligand binding area, 
different from the conventional Sudlow’s sites has also been suggested by several authors.
12-17
 
This binding locus called as the digitoxin site is responsible for the interactions of bile acids, 
digitoxin, digoxin and related cardenolides.
16,18,19
 Neither the lone tryptophan (Trp214 at site 
IIA), nor the Tyr411 residue (site IIIA) is associated with the digitoxin site but some other Tyr 
side chains are strongly involved.
16
 Moreover, this area is not identical with the high-affinity 
fatty acid (FA) binding sites.
18
 In line with these features, a recent study using recombinant 
domains of HSA demonstrated the primary binding of digitoxin to domain I
20
 which contains 
five Tyr residues and hosts a low-affinity FA site.
5,21,22
 
Very recently, circular dichroism spectroscopic (CD) studies have provided several lines of 
evidence for the broad ligand recognition ability of the large cleft in subdomain IB (site IB).
23
 
Beyond a few, crystallographically verified primary ligands of this site including hemin,
6
 a 
bilirubin photoisomer,
7
 a sulphonamide derivative,
8
 and fusidic acid,
7
 the binding of a diverse 
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2 
set of additional chemical compounds has been demonstrated such as suramin, dicoumarol, 
bile acids, biliverdin, camptothecin, teniposide and anthracycline derivatives.
23
 A prominent 
feature of this pocket is its conformational plasticity which allows proper accomodation of 
structurally divergent compounds.
13
 
By employing CD spectroscopy, the present contribution shows that accomodation of 
certain ligand molecules at site IB induces characteristic changes in the near-UV CD 
spectrum of the protein which can be well characterised by using the difference CD 
approach. Subtraction of CD contribution of native HSA from that its ligand-bound 
form in the near-UV region (250-320 nm) results in a difference ellipticity curve 
revealing the conformational changes of the aromatic side chains (Trp, Tyr, Phe).
24
 Such 
a modification of the CD profile of HSA is related to the unique, residue specific structural 
adaptation of the binding pocket prompted by inclusion of some guest compounds (Fig. 1). 
Among that test ligands, bile acids were included due to a previous proposal on their 
non-conventional albumin binding location
12
 as well as their displacing effect observed 
against HSA-bound biliverdin.
23
 Similarly, 18β-glycyrrhetinic acid and carbenoxolone 
have also showed biliverdin competition indicating their accomodation in the site IB 
pocket.
23
 In addition, peer-reviewed crystallographic data demonstrated the subdomain 
IB binding of fusidic acid
7
 while inclusion of ibuprofen and gemfibrozil has been 
postulated based on un-published crystallographic results.
13
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Materials and Methods 
 
Materials 
Human serum albumin (Sigma, 97%, A1887, fatty acid-free), 5β-cholanic acid (Sigma), 
carbenoxolone disodium salt (Sigma), chenodeoxycholic acid (Sigma), ursodeoxycholic acid 
(Sigma), sodium glycochenodeoxycholate (Sigma), sodium glycocholate (Sigma), sodium 
taurocholate (Sigma), dehydroepiandrosterone sulfate (Sigma), diazepam (EGIS 
Pharmaceuticals Plc.), gemﬁbrozil (AK-Scientiﬁc, Inc.), myristic acid (Sigma), palmitic acid 
(Sigma), oleic acid (Fluka), fusidic acid sodium salt (Santa Cruz Biotechnology, Inc.), 18β-
glycyrrhetinic acid (Sigma), and azapropazone (Curry S, Imperial College, London) were 
used as supplied. All other chemicals were of analytical grade. 
 
Preparation of ligand and HSA solutions 
Stock solutions of water soluble compounds were prepared immediately before use in double 
distilled water (carbenoxolone, fusidic acid, glycocholate, taurocholate, 
glycochenodeoxycholate, dehydroepiandrosterone sulfate). DMSO/water mixture (1:1 v/v) 
were used to dissolve chenodeoxycholic acid, ursodeoxycholic acid, and 18β-glycyrrhetinic 
acid. The volume of DMSO added into sample solutions never exceeded 5% (v/v) and caused 
negligible effects on the CD spectra. HSA samples were dissolved in physiological Ringer 
buffer solution (137 mM NaCl, 2.7 mM KCl, 0.8 mM CaCl2, 1.1 mM MgCl2, 1.5 mM 
KH2PO4 and 8.1 mM Na2HPO4⋅12H2O). 
 
Circular dichroism and UV absorption spectroscopic measurements 
CD and absorption spectra were recorded on a Jasco J-715 spectropolarimeter at 25 ± 0.2 °C 
by the use of a rectangular quartz cell of 1 cm optical pathlength (Hellma, USA). Temperature 
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4 
control was provided by a Peltier thermostat equipped with magnetic stirring. Each spectrum 
represents the average of three scans obtained by collecting data at scan speed of 100 nm/min. 
CD curves of ligand-HSA mixtures were corrected by subtracting spectral contributions of 
ligand-free HSA (Fig. 2). 
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5 
Results 
 
Near-UV CD spectroscopic profile of HSA 
 
Since there are no peptide bond transitions in the near-UV region  of proteins (240-320 nm) 
the CD spectrum gives information about the chiral environment around the aromatic side 
chains as well as on the asymmetry of disulfide bridges. HSA contains 18 tyrosines, 31 
phenylalanines, a lone tryptophan residue (Trp214), and 17 pairs of disulfide bonds. 
Accordingly, the near-UV CD curve of HSA is the sum of the intrinsic chiroptical 
contribution of these residues (Fig. 2). In general, Phe side chains display vibrational CD fine 
structure between 255 and 270 nm (
1
Lb transition), whereas signals between 275 and 287 nm 
are attributable to the 
1
Lb band of the phenolic chromophore of tyrosines. The CD contribution 
from 285 to 305 nm can be ascribed to the asymmetrically perturbed 
1
La and
 1
Lb transitions of 
the indole ring of the Trp residues (disulfide bonds give rise to broad, weak signals 
throughout the near-UV spectrum). Therefore, the negative peaks resolved around 262 and 
268 nm most likely are of Phe origin, while the shoulders near 276 and 283 nm can be 
assigned to the tyrosyl residues. The low energy, broad negative tail of the CD curve 
extending to 315 nm represents the disulfide contribution. 
 
Effect of bile acids and steroidal saponins on the near-UV CD spectrum of HSA 
 
Due to the presence of several chiral centers bile acids exhibit intrinsic CD signals which are 
displayed below 220 nm where the n–π
*
 and π–π
*
 transitions of the carboxylate moiety occur. 
Thus, any ellipticity changes observed in the near-UV CD spectra of bile acid-HSA 
complexes can exclusively be ascribed to the structural modification of the protein matrix 
provoked by accomodation of the ligand molecules. In relation to the ligand-free state, 
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6 
addition of chenodeoxycholic (CHN), ursodeoxycholic (URS) and glycochenodeoxycholic 
acid (GCHN) substantially changes the CD spectrum of HSA. Upon increasing the bile acid 
concentration of sample solutions, increase of the ellipticity values of HSA could be observed. 
The difference ellipticity curves obtained by subtracting the CD contribution of the ligand-
free protein from that of the bile acid-HSA complexes display partially resolved negative 
extrema between 275 and 290 nm together with less intense peaks below 270 nm (Fig. 3). It is 
to be noted that these spectral changes started to develop upon addition of the first aliquots of 
bile acid stock solutions. 
The less intense difference CD peaks induced by glycocholic and taurocholic acid were 
displayed only when these ligands were added in excess (Fig. 4). 
HSA binding of carbenoxolone (CRB) and 18β-glycyrrhetinic acid (18β-GLC) gave rise to 
similar results: the difference CD curves exhibited a negative peak and a shoulder around 286 
and 282 nm (Fig. 5). Importantly, in protein-free solution no negative signals are shown in the 
intrinsic CD spectra of these molecules. Distinctly from CRB, the negative ellipticity signals 
induced by 18β-GLC appeared at higher, around a 1:1 steroid:HSA molar ratio. 
Additional steroid ligands of HSA including digoxin and fusidic acid failed to induce any CD 
spectral changes (data not shown). 
 
HSA binding location of bile acids: evaluation by CD displacement experiments 
 
CD markers of the main drug binding regions of HSA can successfully be employed to 
identify binding sites of ligand molecules. In protein bound state, these markers display 
characteristic induced CD (ICD) bands, which decrease upon addition of competing agents 
indicating a common binding area. The subdomain IB binding of CHN, URS, CRB, and GLC 
has previously been verified showing competition with the site IB label biliverdin and 
compound 3.
23
 In the literature, however, there are some data on the subdomain IIA and IIIA 
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7 
binding of bile acids, too.
25,26
 Since these regions also contain tyrosyl residues (Tyr150 in IIA 
and Tyr411 in IIIA) it may occur that the secondary binding of bile acids to site IIA or IIIA is 
the source of the observed ellipticity changes. Therefore, azapropazone
27
 and diazepam,
28
 the 
representative marker ligands of site IIA and IIIA were used to address this issue. The site 
marker-HSA complexes prepared around 0.7:1 drug:HSA ratio exhibit characteristic, 
polyphasic ICD signals (Fig. 6). Upon addition of bile acids (CHN, URS, glycoCHN, 
glycocholic acid), the long-wavelength, negative ICD band of azapropazone and diazepam 
were not affected, but new, negative ellipticity signals induced below 300 nm, superposed on 
the ICD curves of the HSA bound marker drugs. After correction with the induced ellipticity 
contribution of the CD labels, the resulting difference bands display very similar shape and 
position to that found with binary steroid-HSA complexes (Fig. 6). 
 
CD spectroscopic changes induced by HSA association of fatty acids, therapeutic drugs, and 
dehydroepiandrosterone sulfate 
 
The crystallographically verified seven common binding sites of medium and long-chain 
nonesterified FAs are asymmetrically distributed across the three domains of HSA (FA sites 
1-7).
5,29
 The three highest-aﬃnity sites (2, 4, and 5) are situated at the interface between 
subdomain IA and IIA, within IIIA, and IIIB, respectively.
21
 The additional, lower-affinity FA 
sites designated as 1, 3, 6, and 7 are hosted within subdomain IB, IIIA, and IIA/IIB. 
According to NMR studies, only the highest-aﬃnity sites are occupied at 2:1 FA:HSA molar 
ratio but above the ratio of 3:1, population of the lower-affinity sites also begins.
22
 During 
titration of HSA samples with concentrated stock solution of myristic, palmitic, and oleic 
acid, the CD spectrum remained constant up to FA:HSA molar ratio of 3. Above of this value, 
however, negative difference CD peaks were evolved in parallel with the increase of the FA 
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8 
concentration in the sample solutions (Fig. 7). No further ellipticity changes were measured 
after reaching 6 mole equivalents of FA. 
The ligand binding pocket of subdomain IIIA preferentially accomodates stick like molecules 
with a peripherial, negatively charged group 
30
. The antiinflammatory and antilipemic drug 
ibuprofen and gemfibrozil are considered as stereotypical ligands of this site.
4,30
 Up to 1 mole 
equivalent of these drugs, no CD spectral changes were detected. Further raising of the 
drug:HSA ratio resulted in the appearance of multiple, negative difference ellipticity bands 
below 300 nm (Fig. 8). Since ibuprofen is a chiral molecule, the same titration were 
performed by using its pure enantiomers, too. (S)- and (R)-ibuprofen produced very similar 
CD spectroscopic changes to that obtained with the racemic sample (data not shown). Within 
the concentration range applied during the titrations, no intrinsic CD signals of the ibuprofen 
enantiomers could be measured above 250 nm in protein-free buffer solution. 
Dehydroepiandrosterone sulfate (DHEAS) is the principal 17-ketosteroid in peripheral blood 
(~3 µM) where its 95% is bound to HSA (Ka: 6.3 × 10
4
 M
-1
) 
31
. Two sets of HSA binding 
sites, a primary and a secondary one were found for DHEAS, but their location is still 
unknown.
31
 Due to the presence of the chirally perturbed saturated ketone moiety, DHEAS 
exhibits a positive intrinsic CD band of n–π
*
 origin, which completely overlaps with the 
aromatic CD region of HSA (Fig. 9). Upon addition of DHEAS into albumin solution, this 
CD peak shows a striking transformation: in relation to the symmetrical, bell shaped curve 
measured in aqueous buffer, the short-wavelength side of the peak looses intensity and 
displayes a well-resolved vibronic progression (Fig. 9). These prominent spectral alterations 
can be detected from the beginning of the titration, even at low DHEAS:HSA molar ratios. 
The ellipticity contribution superposed on the CD band of HSA bound DHEAS can be 
visualized by a simple arithmetic procedure: subtracting CD values of the steroid recorded in 
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9 
protein-free state from the spectrum measured with HSA results in a negative difference peak 
showing very similar shape and position to that obtained with bile acids (cf. Fig. 3). 
 
Effect of steroids and gemfibrozil on the near-UV CD profile of hemin-HSA complexes 
 
In analogy with the CD titrations when addition of bile acids generated characteristic 
ellipticity signals superimposed on the ICD curve of HSA bound site labels (Fig. 6), the effect 
of bile acids, CRB, GLC, DHEAS and gemfibrozil on the ICD spectrum of hemin-HSA 
complexes was also studied. The large macrocycle of hemin completely occupies the site IB 
cavity where it binds with very high affinity (Ka ~ 10
8
 M
-1
).
6
 Inclusion of hemin induces 
multiple CD peaks allied to its absorption bands.
28,32
 The broad, negative ICD band of hemin 
displayed between 250-300 nm showed neither shape nor intensity changes upon addition of 
these ligands (data not shown). The intrinsic CD peak of DHEAS measured in the presence of 
hemin-HSA complexes is very similar to that found in Ringer buffer but was red shifted by 5 
nm (Fig. 9). 
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10 
Discussion 
 
Taking into consideration the near-UV CD profile of aromatic protein residues, the spectral 
perturbations of HSA induced by the association of various steroidal compounds suggests the 
main contribution of Tyr residues. HSA contains a lone Trp residue in subdomain IIA of 
which 
1
La and 
1
Lb electronic transitions overlap extensively with that of tyrosines. However, 
some spectral features help to distinguish between the Trp and Tyr contributions:
33
 
• the 
1
La transition of Trp lacks any obvious vibronic structure; 
• usually, the 0-0 
1
Lb band of Trp arise between 288 and 293 nm; 
• in contrast to Tyr, the 0-0 
1
Lb band of Trp is more intense than any of the other 
1
Lb 
vibronic bands; 
• the vibrational structure between 275-289 nm is characteristic to the 
1
Lb transitions of 
Tyr side chains. 
Accordingly, the CD spectral perturbation of HSA are associated to the altered 
stereochemistry of some Tyr residues prompted by the binding of ligand molecules. Distinctly 
from bile acids which are optically transparent above 220 nm, conjugated ketone 
chromophores of CRB and GLC show optically active π-π
*
 and n-π
*
 transitions between 220 
and 370 nm.
34
 It may occur that conformational adaptation of a chiral ligand at the protein 
binding site modifies its intrinsic CD pattern. In these molecules, however, the ketone moiety 
is built in a rigid, steroid framework of which asymmetric centers principally determine their 
intrinsic CD bands. Thus, the observed CD spectroscopic changes can not be associated to the 
structural modification of these agents. The similar spectroscopic pattern, two negative CD 
extrema around 282 and 286 nm, induced by different bile acids and saponines also support 
this conlusion (Fig. 3-5). 
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11 
Tyr residues participate in the formation of each principal drug binding region of HSA: 
Tyr138 and Tyr 161 are involved in the ligand binding of subdomain IB, Tyr150 is located in 
the binding cavity of subdomain IIA, while Tyr411 interacts with guest molecules 
accomodated within subdomain IIIA.
5,9,30,35
 Taking into account the CD spectroscopic 
changes only, it could not be clarified which Tyr residues are responsible for the observed CD 
spectroscopic changes. In this context, however, CD displacement experiments provide 
valuable data. In spite of the presence of a site IIA specific marker azapropazone, steroid 
compounds were able to induce near-UV ellipticity changes (Fig. 6). Similarly, the use of the 
site IIIA label diazepam was not able to preclude the development of negative CD signals 
prompted by addition of bile acids. Importantly, long-wavelength ICD band of neither 
diazepam nor azapropazone vanished indicating the formation of diazepam-bile acid-HSA 
and azapropazone-bile acid-HSA ternary complexes in which the drug and steroid molecules 
are bound at distinct sites. These results imply that neither Tyr150 (site IIA) nor Tyr411 (site 
IIIA) side chain is involved in the observed CD spectroscopic changes. 
It is to be noted, however, that hydroxylation pattern of the steroid nucleus in bile acids 
may affect their binding site preference. Distinctly from CHN and URS, 5β-cholanic 
acid lacks any hydroxyl substituent and thus it is the most hydrophobic bile acid. Its 
addition to diazepam-HSA complexes canceled the induced ellipticity bands of the drug 
indicating a shared binding area in subdomain IIIA (Suppl. Fig. 1). In accord with this, 
it has previously been shown that 5β-cholanic acid enhances the ICD signal of HSA-
bound biliverdin due to site IIIA-site IB interdomain cooperative allosteric interaction.
23
 
Similarly to 5β-cholanic acid, lithocholic acid which bears only a single hydroxyl group 
at the 3α position binds to site IIIA as demonstrated by displacement chromatography 
and CD competition experiments using the site IIIA label diazepam and various profen 
drugs.
26,36
 Interestingly, as it is shown in ref. 26 lithocholic acid added even at six-fold 
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12 
molar excess was not able to completely cancel the negative ICD band of diazepam 
above 300 nm. At the same time, however, the positive ellipticity peak of the drug below 
295 displayed a sign inversion: the final ICD curve recorded at lithocholic 
acid/diazepam molar ratio of 6 exhibits two, partially resolved negative peaks between 
280 and 295 nm which are reminiscent to that measured for bile acid-HSA complexes in 
the present study.
26
 This implies that besides subdomain IIIA, an additional lithocholic 
acid binding site might exist in subdomain IB. 
It is also shown that pre-occupation of the cavity of subdomain IB with a hemin molecule 
cancels the ability of ligand molecules to induce difference CD signals which highlights the 
role of tyrosyl residues of this binding region. Crystallographic data have showed that 
accomodation of hemin induces large rotation and un-stacking of the Tyr138 and Tyr161 
residues.
6
 In ligand-free state, the subdomain IB cavity is L-shaped due to the interhelical π-π 
stacking of the phenolic rings, of which ligand binding induced concerted motion transforms 
the pocket into D-shape allowing enough room to completely engulf the large porphyrin 
nucleus. Similarly, inclusion of medium and long-chain FAs into the pocket also un-stacks the 
Tyr residues opening up a hydrophobic tunnel for their alkyl chain
5,29
 (Fig. 10). Due to the 
strong masking effect of the induced ellipticity band of hemin below 300 nm, the tyrosine 
related difference ellipticity signals could not be resolved in the CD spectrum. In contrast, 
these bands can be well observed when the conformational adjustment is induced by optically 
transparent FA molecules (Fig. 7). The fact that the difference CD bands could only be 
detected at large excess of FAs (FA/HSA molar ratio > 3) suggest that the highest-affinity FA 
sites (2 in IA/IIA, 4 in IIIA, and 5 in IIIB) are not involved in this process. The FA binding 
locus in subdomain IB is among the low-affinity FA sites (1 in IB, 3 in IIIA, 6 in IIA, and 7 in 
IIA) which are populated above 3:1 FA:HSA ratio.
22
 It must also be stressed that in contrast to 
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13 
FA site 1, accomodation of FA molecules at the other low-affinity sites (3, 6, and 7) is 
associated with more modest conformational changes of the binding residues.
29
 
The CD spectroscopic results refer to that un-stacking of the Tyr residues may also occur 
upon the site IB binding of bile acids, DHEAS, and steroidal saponines. It seems that proper 
accomodation of these compounds demands rotation of the Tyr138 and Tyr161 side chains 
which disrupts the stacking interaction between them. Noticeably, based on unpublished 
crystallographic data, subdomain IB binding of certain steroid-based therapeutics has been 
claimed to induce similar conformational re-arrangement of that Tyr residues.
13
  
Curiously, HSA binding of ibuprofen above 1:1 molar ratio also induced a characteristic 
difference CD pattern. According to crystallographic studies, besides the primary binding site 
in subdomain IIIA, only a single secondary ibuprofen locus was found in the shallow trench at 
the interface between subdomains IIA and IIB that overlaps the low-affinity FA site 6.
30
 
Solution binding studies employing 2D NMR technique corroborated the association of 
ibuprofen to these sites but also indicated a third, previously unidentiﬁed binding area which 
corresponds to another low-affinity FA site.
22
 In addition, as it has been concluded from 
displacement studies, the specific HSA binding site of glycyrrhizin (the glycosidic form of 
18β-GLC) is largely in common with a low-affinity ibuprofen binding area.37 Taken together, 
it can be presumed that this site is situated within subdomain IB where the Tyr138 and 
Tyr161 residues un-stack upon hosting of the ibuprofen ligand explaining the observed CD 
spectroscopic changes. In concordance with this concept, ibuprofen binding in subdomain IB 
has also been claimed but neither the experimental method nor the crystal structure of the 
complex were reported 
13
. The same is true for gemfibrozil, the association of which to site IB 
(and IIIA) has also been described based on unpublished crystallographic data.
13
 It can be 
assumed that the site IB binding mode of ibuprofen and gemfibrozil is similar to that of FAs:
5
 
the apolar portion of the drug molecule is inserted into the hydrophobic sub-chamber created 
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14 
by un-stacking of the tyrosyl residues, while the carboxylic head forms H-bonds to an 
adjacent basic side chain, e.g. Arg117 (Fig. 10). 
It must be emphasized, however, that spatial re-positioning of the Tyr residues is not 
necessarily occurs during ligand binding to subdomain IB. In contrast to hemin and 
FAs, X-ray structures of other ligand-HSA adducts showed that site IB accomodation of 
the steroid antibiotic fusidic acid, 4Z,15E-bilirubin-IXα, and a sulphonamide derivative 
does not perturb the stacked conformation of the Tyr138-Tyr161 pair.
7,8
 In line with 
this, the present work demonstrated that HSA association of fusidic acid induces no CD 
spectroscopic changes. It seems that similarly to fusidic acid, site IB accomodation of the 
digoxin molecule also requires no conformational adjustment of the tyrosyl residues. 
Understanding what structural features of ligand molecules promote the sterical re-
arrangement of Tyr138 and Tyr161 side chains is still a challenging task for future 
researches.  
Importantly, as the cases of FAs, ibuprofen, gemfibrozil, glyco- and taurocholic acid 
illustrate, CD spectroscopic changes evolved only in ligand excess may refer to the secondary 
site IB binding of these agents. In contrast, development of the difference ellipticity peaks 
below 1:1 ligand:HSA ratio suggests the primary site IB association of guest compounds (e.g., 
CHN, URS, CRB, DHEAS, see Fig. 3 and 4). 
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15 
Conclusions 
 
The present study demonstrates the characteristic modification of the near-UV CD spectrum 
of HSA upon binding of important endogenous as well as therapeutic drug ligands. Taking 
into consideration these results and previously published data, the observed CD spectroscopic 
changes are assigned to the Tyr138 and Tyr161 residues of subdomain IB where bile acids, 
DHEAS, steroidal saponines, FAs, and some pharmaceutical substances are bound. 
Accomodation of these compounds requires un-stacking of the tyrosine side chains defining a 
novel binding environment which is accompanied by negative ellipticity signals in the 
difference CD spectrum. Reported for the first time, this spectroscopic approach can be useful 
to detect site IB accomodation of HSA ligands (especially steroidal compounds), to study the 
ligand binding induced local conformational adaptation of the binding pocket, to disclose the 
formation of ligandIB-ligandIIA/IIIA-HSA ternary complexes, and to differentiate between the 
primary/secondary subdomain IB binding of guest molecules. 
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Figure 1  
Chemical structures of HSA ligands used in this work.  
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Figure 2  
CD and absorption spectra of HSA in the near-UV region measured in the absence and in the presence of 
ursodeoxycholic acid (Ringer buffer, 25 °C). The difference ellipticity curve (‘C’) obtained by subtracting CD 
spectral contributions of the ligand-free HSA (‘A’) is shown.  
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Figure 3  
Difference CD curves measured upon stepwise addition of bile acids to 25 µM HSA (Ringer buffer, 25 ºC).  
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Figure 4  
Difference CD curves measured upon stepwise addition of glycocholic (GCHL) and taurocholic acid (TCHL) 
into HSA solution (Ringer buffer, 25 ºC).  
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Figure 5  
Difference CD curves measured upon stepwise addition of 18β-glycyrrhetinic acid (18β-GLC) and 
carbenoxolone (CRB) to HSA in Ringer buffer at 25 ºC. Bottom panel: CD spectra of carbenoxolone in 
protein-free buffer solution.  
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Figure 6  
Induced CD curves of azapropazone-HSA (top) and diazepam-HSA (bottom) complexes in the absence (‘A’) 
and in the presence (‘B’) of chenodeoxycholic acid (Ringer buffer, 25 ºC). The use of additional bile acids 
including URS, glycoCHN, and glycocholic acid gave rise to similar results.  
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Figure 7  
Difference CD spectra measured upon stepwise addition of nonesterified dietary fatty acids into HSA solution 
(Ringer buffer, 25 ºC).  
171x263mm (300 x 300 DPI)  
 
 
Page 29 of 33
ACS Paragon Plus Environment
The Journal of Physical Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  
 
 
Figure 8  
Difference CD spectra measured upon stepwise addition of (±)-ibuprofen and gemfibrozil into HSA solution 
(Ringer buffer, 25 ºC).  
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Figure 9  
Top panel: CD band of DHEAS in the absence (‘A’) and in the presence (‘B’) of HSA (Ringer buffer, 25 ºC). 
Bottom panel: CD band of DHEAS in Ringer buffer and in hemin-HSA mixture (induced CD contribution of 
HSA bound hemin was subtracted).  
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Figure 10  
Superposition of subdomain IB of ligand-free HSA (PDB: 1E78, light blue tyrosines) and capric acid-HSA 
complex (PDB: 1E7E, green tyrosines) to illustrate the conformational re-arrangement of the Tyr138 and 
Tyr161 side chains. Note the large increase of the inter-residual distance upon insertion of the FA molecule 
(orange). H-bonds formed between capric acid and Arg117 are shown.  
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